Ellipsys Vascular Access System Post Market Surveillance (PS) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-13

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed clinical study is a prospective, non-randomized, multi-center, single-arm, observational, post-market surveillance (PS) study of the Ellipsys Vascular Access System in subjects eligible for arteriovenous (AV) fistula.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae

NCT04896476

Kidney Diseases Arteriovenous Fistula

ACTIVE_NOT_RECRUITING NA

Alucent Vessel Restoration System for AVF

NCT05462223

AV Fistula

RECRUITING NA

FLEX Vessel Prep Prior to Angioplasty in Native Arteriovenous Fistulae (AVF)

NCT05034939

Arteriovenous Fistula Stenosis

COMPLETED NA

Surveillance and Proactive Intervention for Dialysis Access

NCT01391975

Renal Failure Arteriovenous Fistula

WITHDRAWN NA

End-to-side Versus Side-to-side Anastomosis With Distal Vein Ligation for Arteriovenous Fistula Creation

NCT04222881

Arterio-venous Fistula

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this post-market surveillance study is to support the short-term safety of the device and procedure and further assess long-term safety and effectiveness in subjects treated by newly trained providers of the Ellipsys Vascular Access System in the creation of a native AV fistula via percutaneous access in subjects who are on hemodialysis and are medically indicated for the creation of an upper limb anastomosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Disease, End Stage Kidney Disease, End-Stage AV Fistula Fistulas Arteriovenous

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ellipsys Vascular Access System

The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients who have chronic kidney disease requiring dialysis.

Group Type EXPERIMENTAL

Ellipsys Vascular Access System

Intervention Type DEVICE

The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients with a minimum vessel diameter of 2.0mm and less than 1.5mm of separation between the artery and vein at the fistula creation site who have chronic kidney disease requiring dialysis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ellipsys Vascular Access System

The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients with a minimum vessel diameter of 2.0mm and less than 1.5mm of separation between the artery and vein at the fistula creation site who have chronic kidney disease requiring dialysis.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or non-pregnant female ≥ 18 years of age and ≤ 80 years of age
2. Life expectancy of at least one year, in the investigator's opinion
3. Diagnosed with ESRD or chronic kidney disease on hemodialysis.
4. Patients deemed medically eligible for upper extremity autogenous AV fistula creation, per institutional guidelines and/or clinical judgment
5. Adequate quality vein based on pre-operative assessment

1. Adjacent vein diameter of ≥2.0 mm at target anastomosis site
2. Confirmed clinically significant outflow
6. Adequate quality radial artery based on pre-operative assessment

a. Arterial lumen diameter of ≥2.0 mm at target anastomosis site
7. Adequate collateral arterial perfusion with patent palmar arch as demonstrated by Barbeau Test or Allen's Test.
8. Radial artery-adjacent vein proximity ≤1.5 mm measured lumen edge-to-lumen edge as determined by pre-procedural ultrasound and confirmed pre-procedure
9. Patient is able to provide written informed consent and attend follow-up examinations at the enrolling institution

10. Confirm radial artery-adjacent vein proximity ≤1.5 mm measured lumen edge-to-lumen edge as determined by pre-procedural ultrasound and confirmed pre-procedurally
11. Confirm radial artery and adjacent vein diameter of ≥2.0 mm at target anastomosis site

Exclusion Criteria

1. Pre-existing ipsilateral vascular disease interfering with the study procedure or potentially confounding the study results including:

1. Documented or suspected central venous stenosis (≥ 50%) or
2. Upper extremity arterial stenosis or
3. Vascular disease at the radial artery / adjacent vein site
2. Prior vascular surgery at or proximal (central) to the AVF target site interfering with AVF maturation or other ipsilateral surgery that could potentially confound the study results such as prior axillary dissection or mastectomy
3. History of steal syndrome from a previous surgical ipsilateral hemodialysis vascular access which required intervention or abandonment
4. Systolic pressures \< 100 mg Hg at the time of screening
5. Suspected or confirmed skin disease at the skin entry site
6. Edema of the upper extremity on the ipsilateral side
7. Immunocompromised subjects due to underlying disease or immunosuppressant therapy such as sirolimus (Rapamune®) or Prednisone at a dose of \> 10 mg per day
8. Known bleeding diathesis, coagulation disorder or medications putting the subject at increased risk, in the Investigator's judgment
9. Patients with acute or active infection
10. Scheduled kidney transplant within 6 months of enrollment
11. Participation in another clinical investigation (excluding retrospective studies or studies not requiring a consent form)
12. History of substance abuse or anticipated to be non-compliant with medical care or study requirements based on investigator judgment
13. Patient has an active COVID-19 infection with ongoing sequela or hospitalization for treatment of COVID-19.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No